Novartis’ Zolgensma gene therapy study halted by FDA on animal safety concerns
DOMINICK REUTER/AFP/GETTY IMAGES
The hold affects the clinical trial that was testing a higher dose administered by spinal injection to older children with spinal muscular atrophy.
.png)
No hay comentarios:
Publicar un comentario